| 000 | 01825 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250512035337.0 | ||
| 264 | 0 | _c19880726 | |
| 008 | 198807s 0 0 eng d | ||
| 022 | _a0934-9723 | ||
| 024 | 7 |
_a10.1007/BF01962177 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVerschraegen, G | |
| 245 | 0 | 0 |
_aComparative in vitro activity of the new quinolone fleroxacin (RO 23-6240). _h[electronic resource] |
| 260 |
_bEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology _cFeb 1988 |
||
| 300 |
_a63-6 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAmikacin _xpharmacology |
| 650 | 0 | 4 |
_aAmoxicillin _xpharmacology |
| 650 | 0 | 4 | _aAmoxicillin-Potassium Clavulanate Combination |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xpharmacology |
| 650 | 0 | 4 |
_aBacteria _xdrug effects |
| 650 | 0 | 4 |
_aCefaclor _xpharmacology |
| 650 | 0 | 4 |
_aCeftazidime _xpharmacology |
| 650 | 0 | 4 |
_aCefuroxime _xpharmacology |
| 650 | 0 | 4 |
_aCiprofloxacin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aClavulanic Acids _xpharmacology |
| 650 | 0 | 4 |
_aCorynebacterium _xdrug effects |
| 650 | 0 | 4 |
_aDrug Combinations _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 | _aFleroxacin |
| 650 | 0 | 4 |
_aNorfloxacin _xanalogs & derivatives |
| 650 | 0 | 4 | _aPefloxacin |
| 650 | 0 | 4 |
_aPiperacillin _xpharmacology |
| 650 | 0 | 4 |
_aStaphylococcus _xdrug effects |
| 650 | 0 | 4 |
_aVancomycin _xpharmacology |
| 700 | 1 | _aClaeys, G | |
| 700 | 1 | _aVan den Abeele, A M | |
| 773 | 0 |
_tEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology _gvol. 7 _gno. 1 _gp. 63-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF01962177 _zAvailable from publisher's website |
| 999 |
_c3138179 _d3138179 |
||